Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used and whether they are one- or two-sided
- Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) and variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  - Give P values as exact values whenever possible.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about: availability of computer code

| Data collection | No software was used |
|-----------------|----------------------|
| Data analysis   | Stata IC 14.2 [StataCorp LLC, Texas, USA] |

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitLab). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about: availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data are accessible on request (https://neardb.aging.se/study/gas-snac-s).
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences  ☐ Behavioural & social sciences  ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/or-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

**Sample size**
The number of participants attending the GÅS study was decided several years before the initiation of this study. Therefore, it was not possible to influence the sample size. In addition, the wide range of reported estimates of decline in FEV1s in adults makes it difficult to target a specific effect size. Notwithstanding the mentioned constrains, the number of COPD participants in the database was roughly estimated before initiating this study to assess the feasibility of running a mixed model. Assuming that the COPD prevalence in GÅS was similar to that in the overall population (about 7%), the attendance rate was 60%, and that 40% of participants would not have a complete spirometry assessment, over 100 incident COPD cases were expected. This was considered to be sufficient to achieve convergence of the mixed model and thus the study sample was requested from the GÅS committee.

**Data exclusions**
- 370 excluded due to COPD at baseline
- 2,233 participants excluded due to missing spirometry or poor quality spirometry (see Fig 1)

**Replication**
Not applicable

**Randomization**
Not applicable

**Blinding**
Not applicable

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods |
|----------------------------------|---------|
| n/a | Involved in the study | Involved in the study |
| ☒ | Antibodies | ☒ | CHIP-seq |
| ☒ | Eukaryotic cell lines | ☒ | Flow cytometry |
| ☒ | Palaeontology and archaeology | ☒ | MRI-based neuroimaging |
| ☒ | Animals and other organisms | | |
| ☒ | Human research participants | | |
| ☒ | Clinical data | | |
| ☒ | Dual use research of concern | | |